|
Real-time Estimate
Cboe BZX
01:29:14 04/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 59.10 USD | +0.97% |
|
+6.99% | +34.90% |
| 01/09 | Exelixis Wins Appeal in Patent Case Against MSN Laboratories | MT |
| 06/08 | Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EXELIXIS, INC. | Bio Therapeutic Drugs | +1.06% | +6.99% | +34.90% | +59.97% | +199.06% | 1.45TCr |  | | |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
